Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene study reveals clues about ulcerative colitis and drug effectiveness

NCT ID NCT07564895

First seen May 14, 2026 · Last updated May 23, 2026 · Updated 2 times

Summary

This completed study examined whether differences in the BAFF gene are linked to the risk of developing ulcerative colitis and how well the drug vedolizumab works. Researchers analyzed DNA from 841 people with ulcerative colitis to identify gene patterns. The goal was to better understand the disease and potentially guide future treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • the Second Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

Conditions

Explore the condition pages connected to this study.